zinc finger protein 99Genealiases: C19orf9 · F8281
Q-omics provides the consensus-scored ZNF99 profile across patient tissues and cancer cell-line models. ZNF99 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF99 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ZNF99 RNA expression shows 14,875 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where ZNF99 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF99 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF99 survival associations across molecular data types. ZNF99 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (12) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF99 RNA expression–survival associations across cancer types. High ZNF99 expression shows favorable associations in UVM, KIRC, LGG, OV, LUAD and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF99 RNA expression.
This table summarizes ZNF99 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF99. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF99 shows lower tumor expression in KIRC, KIRP, COAD and LUSC and higher tumor expression in LIHC and THCA. The KIRC box plot shows higher ZNF99 RNA expression in normal versus tumor tissue (log2 FC = −0.253, t-test p < 0.001).
This table shows molecular features associated with ZNF99 in patient tissues and cancer cell lines. In patient samples, ZNF99 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF99 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
